Importantly, the efficacy was further enhanced when combined with the FLT3 inhibitor gilteritinib, which upregulates NKG2D ligand expression on AML cells via NFκB2/Rel B signaling pathway. The gene discussed is FLT3; the disease is acute myeloid leukemia.